Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
BIIB122 for Parkinson's Disease
Recruiting0 awardsPhase 2
Spokane, Washington
This trial aims to test the safety and effectiveness of a drug called BIIB122 in individuals with a specific type of Parkinson's Disease caused by a genetic mutation. The study will last for 12 weeks
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service